Solvay Q4 Results Mixed; Cautious 2026 Outlook Issued

Solvay's Mixed Q4: EBITDA Beat, Sales Miss

Belgian chemical company Solvay SA announced mixed financial results for the fourth quarter, posting an adjusted EBITDA of €169 million which was 6 percent ahead of analyst estimates. However, the positive EBITDA figure was offset by sales that fell short of expectations and a cautious financial outlook for 2026.

Q4 Performance Overview

For the quarter ending December 31, sales totaled €995 million, missing the consensus estimate of €1.02 billion. The company reported a 9.6 percent organic decline in sales year-over-year. This downturn was attributed to a 5.6 percent decrease in volumes combined with a 3.7 percent drop in pricing, leading to a 29.8 percent organic fall in underlying EBITDA.

Impact on Business Segments

The company's divisions showed divergent results. The Basic Chemicals division exceeded forecasts with an adjusted EBITDA of €160 million, driven by stable domestic markets and growth in peroxides for the semiconductor industry. Conversely, the Performance Chemicals division underperformed, with adjusted EBITDA of €50 million, 8 percent below estimates. This was due to difficult market conditions, including US tariffs and strong pricing competition from Asia.

Cautious 2026 Outlook and Financial Summary

Looking ahead, Solvay issued a conservative forecast for fiscal 2026. The company projects underlying EBITDA between €770 million and €850 million, below the market consensus of €824 million. Expected free cash flow of at least €200 million also falls short of consensus and the company's targeted dividend payout. Despite the cautious outlook, Solvay declared a full-year gross dividend of €2.43 per share, in line with expectations, and plans for €300 million in cost savings by 2026.

FAQ

Q: What were the main takeaways from Solvay's Q4 results?
A: Solvay's Q4 adjusted EBITDA of €169 million beat estimates, but its sales of €995 million missed expectations, reflecting a mixed performance.

Q: Why is Solvay's 2026 guidance seen as cautious?
A: Its forecast for underlying EBITDA from €770 million to €850 million and free cash flow of at least €200 million for 2026 are both below market consensus expectations.

Q: Which Solvay division performed best in the fourth quarter?
A: The Basic Chemicals division exceeded expectations with an adjusted EBITDA of €160 million, outperforming the Performance Chemicals division.

Source: Investing.com